

Haematologica
HAEMATOL/2018/209965
Version 3

Results from HARMONY: an open-label, multicentre, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis

Simon T. Durrant, Arnon Nagler, Paola Guglielmelli, David Lavie, Philipp le Coutre, Heinz Gisslinger, Charles Chuah, Margherita Maffioli, Savita Bharathy, Tuochuan Dong, Monika Wroclawska, and Joaquin Martinez-Lopez

Disclosures: SD received honorarium and speaker fee from Novartis. AN, PG, DL, HG, MM and JL have nothing to disclose. PC received speaker honorarium from Novartis. CC received honorarium from Novartis. SB, TD and MW are Novartis employee and own stocks from Novartis. We thank Nupur Chaubey and Swetha Sirimalla (Novartis Healthcare Pvt Ltd) for providing medical editorial assistance with this manuscript.

Contributions: SD, AN, PG, DL, PC, HG, CC, MM and JL contributed to the collection of data. SB, TD and MW contributed to the study design. All authors contributed to the analysis of data, drafted and approved the manuscript for submission.